Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon

References

• Davids MS. Is there a right management of Richter’s syndrome? In: Invited Lecture presented at: 2022 Pan Pacific Lymphoma Conference; Hawaii; 2022 Jul 21.
   Google Scholar
• Tsimberidou A-M, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005 Jan 15;103(2):216–228. doi: 10.1002/cncr.20773
   PubMedGoogle Scholar
• Moulin C, Morizot R, Remen T, et al. Clinical and biological characteristics and outcomes of richter transformation: a French multicenter study from the Filo Group. Blood. 2019 Nov 13;134(Supplement_1):4112–4112. doi: 10.1182/blood-2019-128053
   Google Scholar
• Thompson PA, Siddiqi T. Treatment of Richter’s syndrome. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):329–336. doi: 10.1182/hematology.2022000345
   PubMedGoogle Scholar
• Parikh SA, Kay NE, Shanafelt TD. How we treat richter syndrome. Blood. 2014 Mar 13;123(11):1647–1657. doi: 10.1182/blood-2013-11-516229
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311–322. doi: 10.1056/NEJMoa1513257
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Gaidano G. Biology and treatment of richter syndrome. Blood. 2018 Jun 21;131(25):2761–2772. doi: 10.1182/blood-2018-01-791376
   PubMed Web of Science ®Google Scholar
• Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013 Sep;162(6):774–782. doi: 10.1111/bjh.12458
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999 Jul 15;94(2):448–454. doi: 10.1182/blood.V94.2.448
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, O’Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20;24(15):2343–2351. doi: 10.1200/JCO.2005.05.0187
   PubMed Web of Science ®Google Scholar
• Alipour S, Leitch H, Vickars LM, et al. Richter transformation of chronic lymphocytic leukemia: incidence, risk factors and outcome. Blood. 2008 Nov 16;112(11):3179–3179. doi: 10.1182/blood.V112.11.3179.3179
   Web of Science ®Google Scholar
• Fan L, Wang L, Zhang R, et al. Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Sep;53(9):1749–1756. doi: 10.3109/10428194.2012.664845
   PubMed Web of Science ®Google Scholar
• Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to richter syndrome. Br J Haematol. 2008 Jun;142(2):202–215. doi: 10.1111/j.1365-2141.2008.07166.x
   PubMed Web of Science ®Google Scholar
• Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome. Clin Cancer Res. 2009 Jul 1;15(13):4415–4422. doi: 10.1158/1078-0432.CCR-08-3266
   PubMed Web of Science ®Google Scholar
• Briski R, Taylor J. Treatment of richter transformation of chronic lymphocytic leukemia in the modern era. Cancers (Basel). 2023 Mar 20;15(6):1857. doi: 10.3390/cancers15061857
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Robrecht S, Bahlo J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021 Jan;35(1):169–176. doi: 10.1038/s41375-020-0797-x
   PubMed Web of Science ®Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018 May 24;131(21):2357–2366. doi: 10.1182/blood-2017-12-820910
   PubMed Web of Science ®Google Scholar
• Morabito F, Tripepi G, Del Poeta G, et al. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. Eur J Haematol. 2021 Apr;106(4):493–499. doi: 10.1111/ejh.13573
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022 Aug 25;140(8):839–850. doi: 10.1182/blood.2021015014
   PubMed Web of Science ®Google Scholar
• Chatzidimitriou C, Vassilakopoulos TP. Rapidly deteriorating B-CLL at presentation: clonally related burkitt leukemia as an atypical richter transformation? Blood. 2021 Apr 22;137(16):2272. doi: 10.1182/blood.2021010664
   PubMed Web of Science ®Google Scholar
• Imataki O, Uemura M. B-chronic lymphocytic leukemia showed triple transformation, to diffuse large B cell, CD20-negative, and T-cell neoplasm during ofatumumab treatment: a case report. BMC Clin Pathol. 2018 May 22;18(1):5. doi: 10.1186/s12907-018-0072-5
   PubMedGoogle Scholar
• Ge H, Wu X, Shen J, et al. A case report of extranodal NK/T-cell lymphoma in patient with chronic lymphocytic leukemia. Medicine (Baltimore). 2018 Jul;97(30):e11619. doi: 10.1097/MD.0000000000011619
   PubMed Web of Science ®Google Scholar
• Strickler JG, Amsden TW, Kurtin PJ. Small B-cell lymphoid neoplasms with coexisting T-cell lymphomas. Am J Clin Pathol. 1992 Oct;98(4):424–429. doi: 10.1093/ajcp/98.4.424
   PubMed Web of Science ®Google Scholar
• Lee A, Skelly ME, Kingma DW, et al. B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter’s syndrome. Am J Clin Pathol. 1995 Mar;103(3):348–352. doi: 10.1093/ajcp/103.3.348
   PubMed Web of Science ®Google Scholar
• Stephens DM, Boucher K, Kander E, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021 Nov 1;106(11):2845–2852. doi: 10.3324/haematol.2020.256388
   PubMed Web of Science ®Google Scholar
• Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007 Oct;31(10):1605–1614. doi: 10.1097/PAS.0b013e31804bdaf8
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 1;123(18):2783–2790. doi: 10.1182/blood-2013-11-536169
   PubMed Web of Science ®Google Scholar
• Soilleux EJ, Wotherspoon A, Eyre TA, et al. Diagnostic dilemmas of high-grade transformation (Richter’s syndrome) of chronic lymphocytic leukaemia: results of the phase II national cancer research institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology. 2016 Dec;69(6):1066–1076. doi: 10.1111/his.13024
   PubMed Web of Science ®Google Scholar
• Michallet A-S, Sesques P, Rabe KG, et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s syndrome. Leuk Lymphoma. 2016;57(6):1474–1477. doi: 10.3109/10428194.2015.1099643
   PubMed Web of Science ®Google Scholar
• Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006 Aug;47(8):1267–1273.
   PubMed Web of Science ®Google Scholar
• Mato AR, Wierda WG, Davids MS, et al. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 Nov;104(11):2258–2264. doi: 10.3324/haematol.2018.207068
   PubMed Web of Science ®Google Scholar
• Wang Y, Rabe KG, Bold MS, et al. The role of 18F-FDG-PET in detecting Richter’s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica. 2020 Nov 1;105(11):2675–2678. doi: 10.3324/haematol.2019.240564
   PubMed Web of Science ®Google Scholar
• Davids MS, Huang Y, Rogers KA, et al. Richter’s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy. JCO. 2017 May 20;35(15_suppl):7505–7505. doi: 10.1200/JCO.2017.35.15_suppl.7505
   Google Scholar
• Rossi D, Spina V, Deambrogi C, et al. The genetics of richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011 Mar 24;117(12):3391–3401. doi: 10.1182/blood-2010-09-302174
   PubMed Web of Science ®Google Scholar
• Sun T, Susin M, Desner M, et al. The clonal origin of two cell populations in Richter’s syndrome. Hum Pathol. 1990 Jul;21(7):722–728. doi: 10.1016/0046-8177(90)90032-Z
   PubMed Web of Science ®Google Scholar
• Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of richter transformation: experience of 204 patients from a single center. Haematologica. 2020 Mar;105(3):765–773. doi: 10.3324/haematol.2019.224121
   PubMed Web of Science ®Google Scholar
• Davids MS, Rogers KA, Tyekucheva S, et al. Venetoclax plus dose-adjusted R-EPOCH for richter syndrome. Blood. 2022 Feb 3;139(5):686–689. doi: 10.1182/blood.2021011386
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014 Dec;89(12):E239–43. doi: 10.1002/ajh.23841
   PubMed Web of Science ®Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 Jan;180(2):259–266. doi: 10.1111/bjh.15035
   PubMed Web of Science ®Google Scholar
• Dabaja BS, O’Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter’s syndrome. Leuk Lymphoma. 2001 Jul;42(3):329–337. doi: 10.3109/10428190109064589
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 1;97(7):1711–1720. doi: 10.1002/cncr.11238
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196–203. doi: 10.1200/JCO.2007.11.8513
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wierda WG, Wen S, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568–574. doi: 10.1016/j.clml.2013.03.012
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, O’Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter’s syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr;43(4):767–772. doi: 10.1080/10428190290016872
   PubMed Web of Science ®Google Scholar
• Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and marrow transplantation. J Clin Oncol. 2012 Jun 20;30(18):2211–2217.
   PubMed Web of Science ®Google Scholar
• Kim HT, Shaughnessy CJ, Rai SC, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 Sep 8;4(17):4113–4123. doi: 10.1182/bloodadvances.2020002184
   PubMed Web of Science ®Google Scholar
• Herrera AF, Ahn KW, Litovich C, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type richter syndrome. Blood Adv. 2021 Sep 28;5(18):3528–3539. doi: 10.1182/bloodadvances.2021004865
   PubMed Web of Science ®Google Scholar
• Kim HT, Baker PO, Parry E, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation. Haematologica. 2021 Dec 1;106(12):3219–3222. doi: 10.3324/haematol.2021.279033
   PubMed Web of Science ®Google Scholar
• Lahoud OB, Devlin SM, Maloy MA, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation. Blood Adv. 2021 Jul 27;5(14):2879–2889. doi: 10.1182/bloodadvances.2020003726
   PubMed Web of Science ®Google Scholar
• Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of richter syndrome. Blood. 2015 Mar 5;125(10):1676–1678. doi: 10.1182/blood-2014-12-610782
   PubMed Web of Science ®Google Scholar
• Eyre TA, Schuh A, Wierda WG, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol. 2021 Dec;8(12):e912–21. doi: 10.1016/S2352-3026(21)00305-7
   PubMed Web of Science ®Google Scholar
• Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with richter transformation from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016 Dec 2;128(22):60–60. doi: 10.1182/blood.V128.22.60.60
   PubMed Web of Science ®Google Scholar
• Appleby N, Eyre TA, Cabes M, et al. The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019 May 20;19(1):471. doi: 10.1186/s12885-019-5717-y
   PubMedGoogle Scholar
• Tam C, Munoz J, Cull G, et al. Zanubrutinib, alone and in combination with tislelizumab, for the treatment of richter transformation of chronic lymphocytic leukemia. Hemasphere. 2023 Apr;7(4):e870. doi: 10.1097/HS9.0000000000000870
   PubMed Web of Science ®Google Scholar
• Gomez EB, Ebata K, Randeria HS, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023 Jul 6;142(1):62–72. doi: 10.1182/blood.2022018674
   PubMedGoogle Scholar
• Wierda W, Shah N, Cheah CY, et al. Pirtobrutinib in richter transformation: updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study. Blood. 2023 Dec 9;142(Supplement 1):1737–1737. doi: 10.1182/blood-2023-181108
   Google Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5
   PubMed Web of Science ®Google Scholar
• Jurczak W, Shah NN, Lamanna N, et al. Pirtobrutinib (loxo‐305), a next generation highly selective non‐covalent btk inhibitor in previously treated richter transformation: results from the phase 1/2 bruin study. Hematol Oncol. 2021 Jun;39(S2). doi: 10.1002/hon.41_2880
   Google Scholar
• Wierda WG, Lewis DJ, Ghia P, et al. Efficacy of Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in richter transformation: results from the phase 1/2 BRUIN study. Blood. 2022 Nov 15;140(Supplement 1):846–849. doi: 10.1182/blood-2022-157058
   Google Scholar
• Coombs CC, Shah NN, Jurczak W, et al. Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies. JCO. 2023 Jun 1;41(16_suppl):7513–7513. doi: 10.1200/JCO.2023.41.16_suppl.7513
   Google Scholar
• Reiff SD, Mantel R, Smith LL, et al. The BTK Inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation. Cancer Discov. 2018 Oct;8(10):1300–1315. doi: 10.1158/2159-8290.CD-17-1409
   PubMed Web of Science ®Google Scholar
• Woyach J, Stephens DM, Flinn IW, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-Cell lymphoid malignancies. Blood. 2019 Nov 13;134(Supplement_1):4298–4298. doi: 10.1182/blood-2019-127260
   Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 Jun 23;127(25):3215–3224. doi: 10.1182/blood-2016-01-688796
   PubMed Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10;35(8):826–833. doi: 10.1200/JCO.2016.70.4320
   PubMed Web of Science ®Google Scholar
• Davids MS, Rogers KA, Jain N, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with richter syndrome. Hematol Oncol. 2023 Jun;41(S2):466–468. doi: 10.1002/hon.3164_343
   Google Scholar
• Hampel P, Parikh S, Wierda W, et al. P651: venetoclax-based treatment of patients with richter syndrome: outcomes from a multicenter retrospective study. Hemasphere. 2022 Jun 23;6:549–550. doi: 10.1097/01.HS9.0000845488.18043.aa
   Google Scholar
• Hampel P, Parikh S, Wierda W, et al. Venetoclax-based treatment of patients with richter syndrome: outcomes from a multicenter retrospective study. Hemasphere. 2022 May 12;6:549–550. doi: 10.1097/01.HS9.0000845488.18043.aa
   Google Scholar
• Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II study of Umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with Relapsed/Refractory CLL and Richter’s transformation. Blood. 2018 Nov 29;132(Supplement 1):297–297. doi: 10.1182/blood-2018-99-117526
   Google Scholar
• Roeker LE, Shadman M, Svoboda J, et al. Phase I/II study of Umbralisib, Ublituximab, and pembrolizumab in patients with relapsed or refractory chronic lymphocytic leukemia and Richter’s transformation: 5-year follow-up. Presented at: 2021 International Workshop on CLL; 2021 Sep 17–20; virtual. Poster 1083523. 2021.
   Google Scholar
• Iannello A, Vitale N, Coma S, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the bcl-2 inhibitor venetoclax in richter syndrome PDX models. Blood. 2021 Jun 17;137(24):3378–3389. doi: 10.1182/blood.2020010187
   PubMed Web of Science ®Google Scholar
• Ryan CE, Crombie JL, Tyekucheva S, et al. Updated results from a phase I/II study of Duvelisib and Venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or Richter’s syndrome (RS). Blood. 2022 Nov 15;140(Supplement 1):9871–9872. doi: 10.1182/blood-2022-169986
   Google Scholar
• Shouse G, Siddiqi T, Popplewell LL, et al. A phase I trial of PI3Kαδ inhibitor copanlisib in combination with nivolumab in patients with Richter’s transformation (RT) or transformed Non-Hodgkin Lymphoma (tNHL). Blood. 2022 Nov 15;140(Supplement 1):6633–6634. doi: 10.1182/blood-2022-160157
   Google Scholar
• Bou Zeid N, Yazbeck V. Pi3k inhibitors in NHL and CLL: an unfulfilled promise. Blood Lymphat Cancer. 2023 Mar 8;13:1–12. doi: 10.2147/BLCTT.S309171
   PubMed Web of Science ®Google Scholar
• He R, Ding W, Viswanatha DS, et al. PD-1 expression in chronic lymphocytic Leukemia/Small lymphocytic lymphoma (CLL/SLL) and large B-cell richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate Marker for clonal relatedness. Am J Surg Pathol. 2018 Jul;42(7):843–854. doi: 10.1097/PAS.0000000000001077
   PubMed Web of Science ®Google Scholar
• Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and richter transformation or with relapsed CLL. Blood. 2017 Jun 29;129(26):3419–3427. doi: 10.1182/blood-2017-02-765685
   PubMed Web of Science ®Google Scholar
• Armand P, Murawski N, Molin D, et al. Pembrolizumab in relapsed or refractory richter syndrome. Br J Haematol. 2020 Jul;190(2):e117–20. doi: 10.1111/bjh.16762
   PubMed Web of Science ®Google Scholar
• Rogers KA, Huang Y, Dotson E, et al. Use of PD-1 (PDCD1) inhibitors for the treatment of richter syndrome: experience at a single academic centre. Br J Haematol. 2019 Apr;185(2):363–366. doi: 10.1111/bjh.15508
   PubMed Web of Science ®Google Scholar
• Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 2019 Feb;6(2):e67–78. doi: 10.1016/S2352-3026(18)30217-5
   PubMed Web of Science ®Google Scholar
• Jain N, Senapati J, Thakral B, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell richter transformation of CLL. Blood Adv. 2023 May 23;7(10):1958–1966. doi: 10.1182/bloodadvances.2022008790
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Ligtvoet R, Robrecht S, et al. Tislelizumab plus zanubrutinib in patients with richter transformation: primary endpoint analysis of the prospective, multi-center, phase-II RT1 trial of the German CLL Study Group. Blood. 2023 Nov 28;142(Supplement 1):204–204. doi: 10.1182/blood-2023-188705
   Google Scholar
• Al-Sawaf O, Ligtvoet R, Robrecht S, et al. Tislelizumab plus zanubrutinib for richter transformation: the phase 2 RT1 trial. Nat Med. 2024 Jan;30(1):240–248. doi: 10.1038/s41591-023-02722-9
   PubMedGoogle Scholar
• Jain N, Ferrajoli A, Thompson PA, et al. Venetoclax, Obinutuzumab and atezolizumab (PD-L1 checkpoint inhibitor) for treatment for patients with richter transformation. Blood. 2021 Nov 5;138(Supplement 1):1550–1550. doi: 10.1182/blood-2021-154279
   Google Scholar
• Frustaci AM, Montillo M, Rossi D, et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in richter syndrome. JCO. 2023 Jun 1;41(16_suppl):7502–7502. doi: 10.1200/JCO.2023.41.16_suppl.7502
   Google Scholar
• Mato AR, Schuster SJ, Foss FM, et al. A Once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed/refractory richter’s transformation and de novo diffuse large B-Cell Lymphoma. Blood. 2020 Nov 5;136(Supplement 1):21–22. doi: 10.1182/blood-2020-138896
   Google Scholar
• Thompson PA, Jiang X, Banerjee P, et al. A phase two study of high dose blinatumomab in Richter’s syndrome. Leukemia. 2022 Sep;36(9):2228–2232. doi: 10.1038/s41375-022-01649-3
   PubMed Web of Science ®Google Scholar
• Guieze R, Ysebaert L, Roos-Weil D, et al. Blinatumomab for patients with Richter’s syndrome: a multicenter phase 2 trial from the Filo Group. Blood. 2021 Nov 5;138(Supplement 1):3570–3570. doi: 10.1182/blood-2021-147467
   Google Scholar
• Guieze R, Ysebaert L, Roos-Weil D, et al. Blinatumomab for patients with richter syndrome: final results of the phase 2 blinart trial from the Filo Group. Blood. 2022 Nov 15;140(Supplement 1):6631–6632. doi: 10.1182/blood-2022-159695
   Google Scholar
• Kater AP, Ye JC, Sandoval-Sus J, et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022 Nov 15;140(Supplement 1):850–851. doi: 10.1182/blood-2022-158298
   Google Scholar
• Carlo‐Stella C, Hutchings M, Offner F, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with richter’s transformation. Hematol Oncol. 2023 Jun;41(S2):63–65. doi: 10.1002/hon.3163_28
   Google Scholar
• Vaisitti T, Arruga F, Vitale N, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365–3377. doi: 10.1182/blood.2020008404
   PubMed Web of Science ®Google Scholar
• Spurgeon SE, Mei M, Barr PM, et al. Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma. Blood. 2022 Nov 15;140(Supplement 1):6640–6641. doi: 10.1182/blood-2022-163509
   Google Scholar
• Cheah CY, Assouline S, Baker R, et al. Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter’s transformation. Blood. 2023 Nov 28;142(Supplement 1):614–614. doi: 10.1182/blood-2023-173796
   PubMedGoogle Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Benjamini O, Shimoni A, Besser M, et al. Safety and Efficacy of CD19-CAR T Cells in Richter’s transformation after targeted therapy for chronic lymphocytic leukemia. Blood. 2020 Nov 5;136(Supplement 1):40–40. doi: 10.1182/blood-2020-138904
   Google Scholar
• Bensaber H, Bachy E, Beauvais D, et al. Anti-CD19 CAR T-Cell therapy for patients with richter syndrome: a lysa study from the Descar-T Registry. Blood. 2022 Nov 15;140(Supplement 1):3803–3804. doi: 10.1182/blood-2022-158807
   Google Scholar
• Kittai AS, Bond DA, William B, et al. Clinical activity of axicabtagene ciloleucel in adult patients with richter syndrome. Blood Adv. 2020 Oct 13;4(19):4648–4652. doi: 10.1182/bloodadvances.2020002783
   PubMed Web of Science ®Google Scholar
• Kittai AS, Bond DA, Huang Y, et al. Anti-CD19 chimeric antigen receptor T-Cell therapy for Richter’s transformation: an international multicenter retrospective study. Blood. 2023 Nov 28;142(Supplement 1):108–108. doi: 10.1182/blood-2023-180858
   Google Scholar
• Kittai AS, Bond D, Huang Y, et al. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for richter transformation: an international, multicenter, retrospective study. J Clin Oncol. 2024 Mar 29; JCO2400033.
   PubMedGoogle Scholar
• Liang EC, Albittar A, Huang JJ, et al. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023 Sep 29;7(22):6990–7005. doi: 10.1182/bloodadvances.2023011399
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020 Feb 6;382(6):545–553. doi: 10.1056/NEJMoa1910607
   PubMed Web of Science ®Google Scholar
• Parry EM, Leshchiner I, Guièze R, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to richter syndrome. Nat Med. 2023 Jan 9;29(1):158–169. doi: 10.1038/s41591-022-02113-6
   PubMed Web of Science ®Google Scholar
• Nadeu F, Royo R, Massoni-Badosa R, et al. Detection of early seeding of richter transformation in chronic lymphocytic leukemia. Nat Med. 2022 Aug 11;28(8):1662–1671. doi: 10.1038/s41591-022-01927-8
   PubMed Web of Science ®Google Scholar